Company description

The company with ticker AVDL, or Avadel Pharmaceuticals plc, is a specialty pharmaceutical company focused on developing and commercializing novel, patient-centric therapies for diseases with unmet medical needs. With a diverse portfolio of products, Avadel aims to improve the lives of patients through innovative solutions, including controlled-release formulations, novel drug delivery systems, and combination products. The company's flagship product, Noctiva, is the first and only FDA-approved treatment for nocturia, a condition that causes excessive urination at night. Additionally, Avadel has other product candidates in various stages of development that target conditions such as Parkinson's disease, epilepsy, and narcolepsy. With a strong commitment to research and development, as well as strategic partnerships, Avadel is poised for continued growth and success in the pharmaceutical industry.